D
Diagonal Therapeutics
Biotech & Life Sciences · Watertown, United States · Founded 2022
Diagonal Therapeutics leads in pioneering a fresh method for discovering and advancing agonist antibodies in biotechnology MoreLess
Diagonal Therapeutics is a biotechnology company focused on developing innovative agonist antibody therapeutics to treat the underlying causes of debilitating diseases. The company leverages a proprietary platform to create multispecific antibodies, allowing for 10 billion possible combinations, which helps in selecting the best clinical candidates. Diagonal Therapeutics operates in the biopharmaceutical market, primarily serving patients with severe medical conditions that lack effective treatments. The business model revolves around research and development, with revenue generated through partnerships, licensing agreements, and eventual commercialization of successful therapies. The company is led by a team of experienced scientific and business leaders, including CEO Alex, who has a robust background in biotechnology and drug discovery. Diagonal Therapeutics aims to transform patient outcomes by reactivating critical biological pathways.
Keywords: biotechnology, agonist antibodies, multispecific antibodies, clinical candidates, debilitating diseases, biopharmaceutical, research and development, partnerships, licensing, transformative outcomes.
Company overview
Diagonal Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2022
- Headquarters
- Watertown, United States
- Employees
- 31
- Open positions
- 2
- Dealroom signal
- 82.7
Valuation & funding
Diagonal Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jan 2026 | $125M | $500M | Atlas Venture · Viking Global Investors · Paulina Hill · Logos Capital | ↗ |
| SERIES AOther financing | Apr 2024 | $128M | $512M | Lightspeed Venture Partners · RA Capital Management · Velosity Capital · Checkpoint Capital | ↗ |
Growth signals
Diagonal Therapeutics website traffic
Latest recorded traffic for Diagonal Therapeutics is 4.6K monthly website visits, down 14.8% over the last three months. Diagonal Therapeutics's team grew 10.7% over the past year.
Hiring
Open positions at Diagonal Therapeutics
Current openings linked to this company in Dealroom.
Comparisons
Diagonal Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Diagonal Therapeutics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Diagonal Therapeutics has talent and traffic
team presence
In the news
Latest news about Diagonal Therapeutics
Recent press, funding announcements, and product moves mentioning Diagonal Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Diagonal Therapeutics
An AI-synthesized read of the highest-engagement posts about Diagonal Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Diagonal Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.